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Sandra A. Mitchell,1 David Jacobsohn,2 Kimberly E. Thormann Powers,3
Paul A. Carpenter,4 Mary E. D. Flowers,4 Edward W. Cowen,5 Mark Schubert,4
Maria L. Turner,5 Stephanie J. Lee,4 Paul Martin,4 Michael R. Bishop,5 Kristin Baird,5
Javier Bola~nos-Meade,7 Kevin Boyd,3 Jane M. Fall-Dickson,8 Lynn H. Gerber,6
Jean-Pierre Guadagnini,9 Matin Imanguli,5 Michael C. Krumlauf,6 Leslie Lawley,3 Li Li,6
Bryce B. Reeve,10 Janine Austin Clayton,11 Georgia B. Vogelsang,7 Steven Z. Pavletic5The lack of standardized criteria for measuring therapeutic response is a major obstacle to the development
of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National Institutes of Health
(NIH) consensus criteria for evaluating therapeutic response were published in 2006. We report the results
of 4 consecutive pilot trials evaluating the feasibility and estimating the interrater reliability and minimum de-
tectable change of these response criteria. Hematology-oncology clinicians with limited experience in apply-
ing the NIH cGVHD response criteria (n 5 34) participated in a 2.5-hour training session on response
evaluation in cGVHD. Feasibility and interrater reliability between subspecialty cGVHD experts and this
panel of clinician raters were examined in a sample of 25 children and adults with cGVHD. The minimum
detectable change was calculated using the standard error of measurement. Clinicians’ impressions of the
brief training session, the photo atlas, and the response criteria documentation tools were generally favor-
able. Performing and documenting the full set of response evaluations required a median of 21 minutes
(range: 12-60 minutes) per rater. The Schirmer tear test required the greatest time of any single test (median:
9 minutes). Overall, interrater agreement for skin and oral manifestations was modest; however, in the third
and fourth trials, the agreement between clinicians and experts for all dimensions except movable sclerosis
approached satisfactory values. In the final 2 trials, the threshold for defining change exceeding measurement
error was 19% to 22% body surface area (BSA) for erythema, 18% to 26% BSA for movable sclerosis, 17% to
21% BSA for nonmovable sclerosis, and 2.1 to 2.6 points on the 15-point NIHOral cGHVD scale. Agreement
between clinician-expert pairs was moderate to substantial for the measures of functional capacity and for
the gastrointestinal and global cGVHD rating scales. These results suggest that the NIH response criteria are
feasible for use, and these reliability estimates are encouraging, because theywere observed following a singleDivision of Cancer Control and Population Sciences, Na-
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1620 Biol Blood Marrow Transplant 17:1619-1629, 2011S. A. Mitchell et al.2.5-hour training session given at multiple transplant centers, with no opportunity for iterative training and
calibration. Research is needed to evaluate inter- and intrarater reliability in larger samples, and to evaluate
these response criteria as predictors of outcomes in clinical trials.
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detectable changeINTRODUCTION
Although new treatment approaches for chronic
graft-versus-host disease (cGVHD) are emerging,
progress in the development of new therapies has
been limited by the absence of criteria for evaluating
responses that are reliable, valid, sensitive to change,
and accepted for use in clinical trials [1,2]. In 2006,
the National Institutes of Health (NIH) Consensus
Development Project on Criteria for Clinical Trials
in Chronic GVHD proposed a series of measures for
evaluating therapeutic response in cGVHD [3]. The
NIH cGVHD therapeutic response criteria are com-
prised of core and ancillary measures, and include
both clinician-assessed and patient-reported compo-
nents. The core measures include organ-specific mea-
sures of skin, mouth, and eye involvement, as well as
global ratings of cGVHD severity from both clinician
and patient perspectives [3]. The patient-reported out-
come of cGVHD symptom bother is included as a core
measure in the response criteria, and is evaluated using
the Lee cGVHD Symptom Scale [4]. Ancillary mea-
sures of response include performance-based measures
of physical function such as grip strength and 2-minute
walk time, and a variety of patient reported-outcomes
including functional status and health-related quality
of life. However, the feasibility and reliability of these
consensus criteria for use in evaluating adults and chil-
dren with a range of cGVHD manifestations have not
been defined. Evaluation of the concordance between
subspecialty cGVHD experts and transplant clinicians
in scoring measures of response represented the next
logical step in exploring the reliability and validity of
the NIH response criteria. Determining if clinicians’
scoring of response reproduces the scoring of an expert
is fundamental to further development of the criteria
and their application in prospective clinical trials [5].
We conducted 4 pilot studies to (1) explore the fea-
sibility of using the NIH cGVHD response criteria for
evaluating adult and pediatric patients with cGVHD,
and (2) develop preliminary estimates of the interrater
reliability and minimum metrically detectable differ-
ence between subspecialty experts and a group of
hematology-oncology clinicians with limited experi-
ence in cGVHDwho had received a single educational
session about the NIH response criteria. A secondaryobjective was to develop and evaluate the teaching ma-
terials and data collection tools that facilitate use of the
response criteria in clinical trials.MATERIALS AND METHODS
This prospective study was conducted at 3 sites be-
tweenMay 2005 and October 2006. The study was ap-
proved by the institutional review boards of the Center
for Cancer Research, Bethesda, MD, Northwestern
University, Chicago, IL, and Fred Hutchinson Cancer
Research Center, Seattle, WA. Two of the trials were
conducted in 1 site (trial 1 and trial 3), whereas trials 2
and 4 were each conducted at a single center. All par-
ticipants provided written informed consent.
Hematology-oncology clinicians (attending physi-
cians, fellows, nurse practitioners, and physician’s
assistants) (n 5 34) with limited experience with
cGVHD or with the NIH cGVHD response criteria
participated in a 2.5-hour training session designed
to provide an overview of comprehensive response
evaluation in cGVHD. They also received a syllabus
and a photo atlas illustrating common oral, ocular,
and dermatologic manifestations of cGVHD [6].
Participants represented a spectrum of experience,
ranging from hematology-oncology fellows or nurse
practitioners with little experience in stem cell trans-
plantation and cGVHD (n5 17) to experienced trans-
plant clinicians with expertise in managing patients
with cGVHD (n 5 17). In the final 2 trials, all of the
clinician raters had experience in stem cell transplant
and cGVHD; however, across all 4 trials, none of the
clinician raters had experience applying the NIH re-
sponse criteria in evaluating patients. Clinician raters
were eligible to participate in only 1 trial. Within 24
hours following the training session, the clinician
raters applied the NIH response measures in evaluat-
ing adult or pediatric patients with cGVHD. Ratings
made by cGVHD experts in their respective areas
(transplantation, dermatology, oral medicine, and re-
habilitation) represented the standard against which
interrater reliability was determined. The clinician
and expert evaluations of each panel of patients were
conducted in an ambulatory clinic setting over a period
of 4 to 6 hours. In each of the 4 sequential trials, a panel
Biol Blood Marrow Transplant 17:1619-1629, 2011 1621Feasibility and Reliability of the NIH cGVHD
Therapeutic Response Measuresof 4 experts was assembled to perform subspecialty-
focused evaluations (dermatology, oral medicine, reha-
bilitation, and transplantation) of each studyparticipant.
Chronic GVHD experts were organ system/subspe-
cialty experts with substantial experience in evaluating
andmanaging patientswith cGVHD. In each trial, these
cGVHD experts evaluated all patients immediately
before the evaluation conducted by the clinician raters
(N 5 8, N 5 10, N 5 9, and N 5 7 clinician raters
in trials 1 through 4, respectively). The experts were
not permitted to interact with the clinician raters until
all study-related procedures were concluded. To ensure
that each examiner remained blinded to the ratings of
other examiners, the scoring sheets were collected by
the study investigators immediately after the experts
or clinician raters had completed each evaluation of
the patient, and the ratings of each study participant
were known only to the principal investigator and the
study team.
Feasibility, acceptability, and interrater reliability
between experts in cGVHD (transplantation, derma-
tology, oral medicine, and rehabilitation medicine)
and the 34 clinician raters were examined using 25 pe-
diatric and adult patients with varying manifestations
of cGVHD. Feasibility was evaluated by measuring
the time required to perform both the total evaluation
and specific components of the evaluations. Time was
considered one of the most important components of
operational feasibility. A second dimension of feasibil-
ity was examined by asking the nonexpert clinicians to
rate the extent to which (1) the training session pro-
vided the skills necessary to conduct the response eval-
uations, and (2) the measures and data capture forms
were acceptable and easy to use. Reliability estimates
from each trial and feedback from participants were
used to further modify the therapeutic response mea-
sures and the training tools, and these revisedmaterials
were then tested in subsequent trials.Statistical Analysis
Descriptive statistics were used to report partici-
pants’ demographic and clinical characteristics, and
the feasibility dimensions. Extent of agreement be-
tween clinician assessors and expert raters was quanti-
fied in several ways, as recommended by Sanchez and
Binkowitz [5]. First, we created a difference score for
each clinician-expert pair (difference5 clinicianminus
expert score), and examined the distributional proper-
ties of those difference scores with Bland-Altman
plots, graphing the differences against the expert score.
Bland-Altman plots were used to evaluate whether the
difference between the clinician and expert assess-
ments varied as a function of the extent of cGVHD
involvement. The intraclass correlation coefficient
(ICC) was used to quantify concordance between
each clinician-expert pair. In calculating the ICC, a sin-gle-measure, 2-way mixed effects, absolute agreement
model was specified where patients were interpreted as
a random effect, and raters were interpreted as a fixed
effect [7]. This ICC was chosen because raters were
a convenience sample who, it may be argued, were
more motivated and interested in cGVHD than a
random selection of raters [8]. Absolute agreement
measures rather than consistency agreement measures
were computed because systematic differences among
levels of ratings may have been relevant (that is, there
may have been systematic differences when scoring
lower levels of body surface area (BSA) involvement
versus higher levels of BSA involvement) [9]. In
addition, because evaluation of therapeutic response
in trials typically relies on the rating provided by a
single-clinician, rather than combining scores among
several raters, the single-measures ICC, rather than
the average-measures ICC, is reported throughout this
paper [10]. According to interpretive rules for the ICC
proposed by Landis and Koch [11], an ICC of 0.21 to
0.40 represents fair agreement, 0.41 to 0.60 represents
moderate agreement, 0.61 to 0.80 substantial agree-
ment, and 0.81 to 1.00 almost perfect agreement.
A further goal in the analysis was to characterize
the measurement error associated with the different
graders using the response criteria in evaluating pa-
tients with cGVHD. We examined this in 2 ways.
First, we created agreement parameters (# agree-
ments/[# agreements1 # disagreements]) by reporting
the percentage of clinician-expert pairs who (1) dif-
fered by less than610%BSA for cutaneous manifesta-
tions, or (2) fell within 61 point on the 15-point NIH
Oral cGHVD scale. The criteria for these agreement
parameters were extrapolated from the definitions of
partial and complete response for skin and oral mani-
festations, as proposed by Pavletic et al. [3] and repre-
sent the minimum threshold of change that would
need to be observed in order to detect partial or com-
plete response in cutaneous or oral manifestations.We
also determined the percentage of clinician-expert
pairwise values that (1) fell within the 95% confidence
interval (CI) of the expert’s value for the functional
evaluations of 2-minute walk distance and grip
strength, or (2) differed by 61 point or less on the
cGVHD global assessment scales.
Finally, to complement the interpretation of the
intraclass correlation coefficients, we also calculated
the minimum metrically detectable change (MDC95)
associated with rating cutaneous and oral cGVHD
manifestations. The MDC95 provides an anchor
when interpreting change scores, because only when
that change score exceeds the MDC95 can the re-
searcher conclude with 95% confidence that the
change represents true change and not measurement
error [12]. Thus, the MDC95 offers a data-driven ap-
proach to aid in the interpretation of change scores
and sample size estimation [13]. The following
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standard deviation  [square root (12ICC value]) 
1.96 (standard normal score associated with a 2-tailed
95% CI). The population standard deviations were
based on data from an ongoing cGVHD natural his-
tory study at the National Cancer Institute (N 5 155)
(#NCT00331968). These means and standard devia-
tions (erythema 8.5%6 15.1% BSA; movable sclerosis
6.9% 6 15% BSA; nonmovable sclerosis 9.6% 6
17.8% BSA; oral 1.96 6 2.0 points) are comparable
to those recently reported in another series [14].
All analyses were conducted using SPSS version 17
(IBM Corporation, Somers, NY). The number of rat-
ing tasks (defined as the number of clinician-expert
pairwise comparisons) available for analysis in each
trial is specified in the tables where the interrater
reliability results are presented. Missing data are
accounted for by the fact that some of the patient par-
ticipants did not have sufficient endurance to tolerate
complete examinations by all clinicians. When they
so requested, patient participants were given short
breaks from the examinations to rest, and this resulted
in a small amount of missing data.RESULTS
Patient Characteristics
The patient sample (N 5 14 adults; N 5 11 chil-
dren) had a mean age of 33.5 years (range: 3-70 years),
and was predominantly male (64%). Most had under-
gone stem cell transplantation for a diagnosis of acute
leukemia (44%) or chronic leukemia, lymphoma, or
multiple myeloma (28%). Approximately two-thirds
had received a reduced intensity conditioning (RIC)
regimen (60%) and a matched sibling donor graft
(60%). The stem cell source was peripheral blood in
approximately 80% of the patient participants. The
Karnofsky/Lansky Performance Status was deter-
mined to be greater than or equal to 80% in 72% of
the patient participants.
Patients were a median of 40 months posttrans-
plantation (range: 5-195 months). More than two-
thirds of the sample had moderate to severe cGVHD,
as defined by the NIH global severity scoring [14],
with a median of 4 (range: 1-7) organ sites involved.
Based on the NIH diagnostic criteria [15], cGVHD
onset was classified in a majority as progressive
(52%), with the remainder classified as quiescent
(24%) or de novo (24%). Patients were a median of
34 months (range: 2-188 months) from the diagnosis
of cGVHD, and a majority of the patient participants
were receiving moderate (single agent/modality 6
prednisone $0.5 mg/kg/day) (36%) or high (2 or
more agents/modalities 6 prednisone $0.5 mg/kg/
day) (48%) levels of systemic immunosuppression.The sample characteristics relative to the dimen-
sions evaluated in the NIH cGVHD response criteria
were derived from the expert raters and are presented
inTable 1. As seen in the values for standard deviations
about the mean, there was sizable variability observed
in the scoring of involved BSA of cutaneous manifesta-
tions, including erythema, movable, and nonmovable
sclerosis. Mean values for cGVHD self-reported
symptom bother were moderate among participants
in the first 2 trials, and lower levels of symptom bother
were noted among participants in the third and fourth
trials. In general, few participants experienced esopha-
geal, upper, or lower gastrointestinal (GI) symptoms.
Feasibility
The median total time for the novice clinician
raters to complete and document all response evalua-
tions was 21 minutes (range: 12-60 minutes). The oral
examination required a median of 3 minutes; skin
evaluation a median of 6 minutes, and grip strength
and walk time a median of 7 minutes. The Schirmer’s
tear test required the greatest amount of time of any
single test (median: 9 minutes). The median total time
for the patients to complete all 5 self-report measures
(MOS-Short Form 36, Human Activity Profile, Func-
tional Assessment of Cancer Therapy, Lee Chronic
GVHD Symptom Scale, and NIH Response Criteria
Form B) was 15 minutes (range: 8-22 minutes).
In terms of feasibility across all 4 trials, clinicians
offered a generally favorable evaluation of the training
session,withmore than 70%reporting that the practice
opportunities embedded in the training session were
helpful in building the necessary skills to perform spe-
cific procedures such as grip strength evaluation and
the 2-minute walk distance. At least two-thirds of clini-
cian raters indicated that the photo atlas of cutaneous
and oral cGVHDmanifestations was extremely helpful
in recognizing and describing cGVHD clinical fea-
tures. Three-quarters of participants agreed that over-
all the response evaluation documentation tools were
clearly presented, well-organized, and easy to com-
plete. Nonetheless, at least one-half of the clinician
raters believed that incorporating these response as-
sessments into their routine practices or asking com-
munity oncologists and oncology advanced practice
nurses to perform these response evaluations in their
clinics would be challenging.
Interrater Reliability
Metrics of agreement between the expert and clini-
cian raters across the 4 trials to evaluate cutaneous and
oral cGVHDmanifestations are presented in Tables 2
and 3 and in Figure 1. Themedian ICCwas typically in
the range of 0.5 to 0.6, suggesting moderate agree-
ment, with a trend for the highest ICCs to be noted
in the final 2 trials. The mean difference score (the
Table 1. Chronic GVHD Characteristics in the Sample
Overall Trial 1 Trial 2 Trial 3 Trial 4
(n 5 25) (n 5 4) (n 5 6) (n 5 5) (n 5 10)
Cutaneous cGVHD body surface area (BSA) involved
Erythema (mean %BSA/SD) 20.9 (26.5) 30.0 (47.6) 19.3 (23.2) 11.9 (15.8) 22.9 (27.8)
Movable sclerosis (mean %BSA/SD) 14.1 (15.6) 17.5 (17.1) 16.9 (17.8) 22.7 (20.9) 3.4 (5.5)
Nonmovable sclerosis (mean %BSA/SD) 13.4 (18.3) 14.5 (23.7) 3.7 (4.9) 9.6 (12.6) 16.1 (21.1)
Presence of ulcers 6 (24%) 1 (25%) 2 (33%) 3 (60%) 0 (0%)
NIH oral cGHVD scale (0-15-point scale) (mean/SD) 4.2 (2.1) 5.3 (2.4) 3.5 (0.6) 4.4 (1.7) 4.1 (2.8)
Schirmer’s tear test (mm of wetting) (mean/SD) 10.6 (8.9) 5.9 (11.4) 8.9 (6.1) 11.2 (9.8) 13.4 (8.7)
2-Minute walk distance (total feet/2 minutes) (mean/SD) 563 (147.3) 655 (63.5) 367 (173.4) 598 (66.3) 502 (182.3)
Grip strength (psi) (mean/SD) 50.8 (32.1) 59.8 (31.9) 23.8 (20.0) 68.2 (33.3) 37.2 (28.5)
Lee cGVHD symptom bother (0-100-point scale; higher scores
reflect greater cGVHD symptom bother) (mean/SD)
18.9 (13.4) 22.3 (12.9) 24.9 (21.1) 14.8 (10.5) 17.5 (13.7)
Upper GI symptoms (early satiety, anorexia, nausea/vomiting)
None 21 (84%) 4 (100%) 4 (67%) 4 (80%) 9 (90%)
Mild, occasional symptoms 2 (8%) 0 (0%) 0 (0%) 1 (20%) 1 (10%)
Moderate, intermittent symptoms; no reduced intake 1 (4%) 0 (0%) 1 (17%) 0 (0%) 0 (0%)
Severe, persistent symptoms; marked reduction intake 1 (4%) 0 (0%) 1 (17%) 0 (0%) 0 (0%)
Esophageal symptoms
None 21 (84%) 4 (100%) 5 (83%) 4 (80%) 8 (80%)
Occasional dysphagia/odynophagia with solid food/pills 3 (12%) 0 (0%) 0 (0%) 1 (20%) 2 (20%)
Intermittent dysphagia/odynophagia with solid food/pills 1 (4%) 0 (0%) 1 (17%) 0 (0%) 0 (0%)
Dysphagia or odynophagia for almost all oral intake 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Lower GI symptoms
None 19 (76%) 3 (75%) 4 (67%) 5 (100%) 7 (70%)
Occasional loose or liquid stools 2 (8%) 0 (0%) 0 (0%) 0 (0%) 2 (20%)
Intermittent loose or liquid stools throughout the day 4 (16%) 1 (25%) 2 (33%) 0 (0%) 1 (10%)
Voluminous diarrhea requiring intervention 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Clinician rating of cGVHD symptom severity (0-10-point scale)
(Mean/SD)
4.9 (2.1) 4.8 (1.0) 6.5 (1.5) 5.0 (2.9) 4.1 (2.0)
Chronic GVHD NIH severity score
Mild 7 (28%) 1 (25%) 0 (0%) 2 (40%) 4 (40%)
Moderate 8 (32%) 0 (0%) 4 (67%) 1 (20%) 3 (30%)
Severe 10 (40%) 3 (75%) 2 (33%) 2 (40%) 3 (30%)
Clinician evaluation of cGVHD evolution over past month
Improved 10 (40%) 3 (75%) 1 (17%) 1 (20%) 5 (50%)
Worsened 3 (12%) 0 (0%) 1 (17%) 1 (20%) 1 (10%)
Unchanged 12 (48%) 1 (25%) 4 (67%) 3 (60%) 4 (40%)
GVHD indicates graft-versus-host disease; cGVHD, chronic graft-versus-host disease; GI, gastrointestinal; NIH, National Institutes of Health; SD,
standard deviation.
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nician rater) ranged from 10.4 (SD 64.2) to 21.7 (SD
69.6) percent BSA for erythema, from 9.1 (SD 66.5)
to 17.0 (SD 68.9) percent BSA for movable sclerosis,
and from 7.2 (SD 63.2) to 19.0 (SD 66.2) percent
BSA for nonmovable sclerosis. Across the 4 trials, the
mean absolute difference score for oral manifestations
ranged from 1.6 (SD 60.48) to 2.7 (SD 61.5).
The clinician-expert difference scores (mean dif-
ference and 95% CI) for the 10 patients evaluated in
the final trial plotted against the expert’s scores for
those patients are portrayed in Figure 1. The plots re-
veal the heterogeneity in the extent of cGVHDcutane-
ous and oral manifestations present in our sample of
patients, and show that there was fair agreement be-
tween clinicians and the experts across all levels of
cGVHD involvement. Relative to the experts, clinician
raters tended to overestimate the BSA involved with
movable sclerosis and underestimate the extent of
oral involvement with cGVHD.
We also calculated agreement parameters to gauge
if the proposed NIH response criteria were sensitive
enough to accurately detect partial response in bothcutaneous and oral evaluations (ie, capable of accu-
rately detecting a change within 25% to 50% of total
BSA involved with cutaneous manifestations, and for
oral manifestations, within 1 point on the 15-point
NIH Oral cGHVD scale) [3]. For example, in some-
one with BSA of 60% of skin involvement, they must
demonstrate an improvement to 30% of BSA involve-
ment if they are to be classified as partial response [3].
However, if there is 25% BSA involvement or less,
only a complete resolution of all findings is considered
as a response [3]. Extrapolating from this logic of ac-
curately defining partial response, we projected that
an agreement within 610% BSA represents a mini-
mally acceptable limit of pairwise agreement between
clinician and expert. Following a parallel logic for the
15-point scale for rating oral manifestations, we de-
fined acceptable agreement as having occurred when
clinician and expert scores agreed within 61 point.
As shown in Table 2, in rating erythema in the final
2 trials, between 54% and 61% of the time the
clinician-expert pairs differed by less than 610%
body surface area. For movable sclerosis, 55% to
72% of the clinician-expert assessments agreed within
Table 2. Interrater Variability for Evaluation of Cutaneous Manifestations of cGVHD
Median Intraclass
Correlation
Coefficient (ICC)
Absolute Difference
Between Clinician and
Expert %BSA Scores,
Mean (±SD)
Limits of Agreement
Clinician-Expert
Concordance within
± 10% BSA, n (%)
Minimum Metrically
Detectable Change
(MDC95) in Percent BSA
Trial 1 (adults [n 5 4] 28 rating tasks)
Erythema 0.88 21.72 (9.60) 9 (32%) 10
Movable sclerosis 0.33 16.98 (11.65) 13 (46%) 24
Nonmovable sclerosis 0.23 19.01 (6.18) 14 (50%) 30
Trial 2 (pediatrics [n 5 6] 60 rating tasks)
Erythema 0.07 16.48 (4.55) 36 (60%) 28
Movable sclerosis 0.21 17.04 (8.90) 30 (50%) 26
Nonmovable sclerosis 0.16 12.27 (7.52) 43 (72%) 32
Trial 3 (adults [n 5 5] 44 rating tasks)
Erythema 0.47 10.42 (4.25) 27 (61%) 22
Movable sclerosis 0.60 11.35 (4.09) 24 (55%) 18
Nonmovable sclerosis 0.62 10.44 (8.87) 31 (70%) 21
Trial 4 (adults and pediatrics [n 5 10] 65 rating tasks]
Erythema 0.57 16.31 (3.10) 35 (54%) 19
Movable sclerosis 0.24 9.12 (6.52) 47 (72%) 26
Nonmovable sclerosis 0.76 7.19 (3.18) 47 (72%) 17
BSA indicates body surface area; SD, standard deviation; cGVHD, chronic graft-versus-host disease.
1624 Biol Blood Marrow Transplant 17:1619-1629, 2011S. A. Mitchell et al.610% BSA; and for nonmovable sclerosis, 70% to
72% of the assessments were within 610% body sur-
face of involvement. The mean absolute difference be-
tween clinician-expert pairs declined across the course
of the 4 trials, and in the final 2 trials, only the param-
eter for erythema exceeded a mean absolute difference
of 11% BSA. Between 43% and 58% of the time in the
last 2 trials, clinicians rated oral manifestations within
61 point of the experts on the 15-point NIH Oral
cGHVD scale (see Table 3).
Consistent with these observations, the MDC95 in
the last 2 trials ranged from 19% to 22% BSA for ery-
thema, 18% to 26%BSA for movable sclerosis, 17% to
21% BSA for nonmovable sclerosis, and 2.1 to 2.6
points on a 15-point scale for oral cGVHDmanifesta-
tions. These MDC95 estimates suggest that when ob-
served change across time exceeds these estimates,
one can conclude with 95% confidence that the change
is unlikely to have occurred because of interrater mea-
surement error alone.
As summarized in Figure 2, concordance between
clinician and expert pairs was quite high for the ratings
of upper gastrointestinal, lower gastrointestinal, and
esophageal symptoms. On more than 90% of occa-Table 3. Interrater Variability for Evaluation of Oral Manifestation
Median Intraclass
Correlation Coefficient
(ICC)
Absolute
between C
Expert Score
Trial 1 (adults [28 rating tasks])
Oral manifestations 0.50 2.23
Trial 2 (pediatrics [60 rating tasks])
Oral manifestations 0.44 1.57
Trial 3 (adults [40 rating tasks])
Oral manifestations 0.57 2.71
Trial 4 (adults and pediatrics
[66 rating tasks])
Oral manifestations 0.70 1.61
cGVHD indicates chronic graft-versus-host disease.sions, the clinicians scored within 61 point of the
experts, and on at least two-thirds of the occasions,
clinician-expert rater pairs were fully concordant. For
the measures of functional capacity (specifically the
distance walked in 2 minutes and grip strength), more
than 60% of the time, the clinicians and experts were
in complete accord, as defined by the 95% CI around
the expert’s value for 2-minute walk distance and grip
strength.Relative to global ratings of cGVHDseverity,
50% to 75%of the pairwise assessments of cGVHDse-
verity in the final 2 trialswere fully concordant. In glob-
ally rating cGVHD on a 7-point scale as better, worse,
or stable over the past month, 40% to 63% of the rat-
ings by the clinician-expert pairswere fully concordant,
and 80% to 100% of the ratings were within61 point.
However, in rating cGVHD symptom severity on
a 0-10 scale, agreement between clinician and expert
was modest; 33% to 60% of the time the difference
between clinician and expert exceeded 2 points.DISCUSSION
This study examined the feasibility and interrater
reliability of the NIH cGVHD response criterias of cGVHD
Difference
linician and
, Mean (±SD)
Limits of Agreement
Clinician-Expert
Concordance within 1 point
on a 15-Point scale
Minimum Metrically
Detectable Change
(MDC95)
(15-Point Scale)
(0.96) 11 (39%) 2.7 points
(0.60) 36 (60%) 2.9 points
(1.51) 17 (43%) 2.6 points
(0.48) 38 (58%) 2.1 points
Figure 1. Bland-Altman plots, comparing differences (Trial 4) between clinician and expert scoring of cutaneous and oral cGVHD manifestations (dif-
ference 5 clinician score minus expert score) plotted against expert scores. Negative differences reflect clinician underestimation of the extent of in-
volvement, whereas positive differences reflect clinician overestimation of the extent of involvement, relative to the expert’s assessment. A change in the
magnitude of the difference between clinician and expert assessments with increasing extent of cGVHD involvement, as assessed by the expert, is
determined by looking for patterns along the x-axis.
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of cGVHD manifestations in 4 successive pilot trials.
We observed that use of the NIH response criteria is
feasible for clinicians and patients because the median
time taken to complete the evaluation is appropriate
for what might be expected for the complex care visits
that typically occur periodically within the context of
a clinical trial. However, a single training session is
insufficient to achieve consistently acceptable inter-
rater agreement. With refinement of the measures
(clarification of the definitions of movable and non-
movable sclerosis, modification of the scale for gradingoral manifestations) and enhancements to the training
materials, agreement between clinicians and experts in
rating selected domains of response improved across
the 4 successive trials. For cutaneous erythema, non-
movable sclerosis, and oral manifestations, agreement
between clinician-expert pairs approached what are
considered fair levels of interrater reliability for
a new measure [11]. Based on our findings, a clinical
trial participant would need to demonstrate a change
from baseline in the range of 19% to 22% BSA for er-
ythema, 18% to 26% BSA for movable sclerosis, 17%
to 21% BSA for nonmovable sclerosis, and 2.1 to 2.6
Figure 2. Interrater agreement between clinicians and experts for evaluation of gastrointestinal symptoms, functional performance, and cGVHD global
scores. In the final 2 trials, substantial interrater agreement was observed in evaluating gastrointestinal symptoms (68% to 94% of pairwise comparisons
in perfect agreement), whereas moderate to substantial agreement was noted in evaluating the 2-minutewalk (75% to 80% of pairwise assessments were
concordant), grip strength (60% to 77% of pairwise assessments were concordant), cGVHD global severity (clinician-expert pairs in perfect agreement
50% to 75% of the time), and cGVHD evolution over the past month (clinician-expert pairs in perfect agreement 40% to 63% of the time). Note: Num-
bers were rounded so that values add to 100%.
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conclude with 95% confidence that the changes were
not attributable to variability in scoring when different
raters perform the evaluation. Of note, the MDC95 for
the 15-point NIHOral cGVHD scale falls well within
the 4-point absolute minimum change criterion pro-
posed to establish partial response [3]. These conclu-
sions must be tempered by the fact that in the final 2
trials, raters had transplant experience. Conversely,
earlier trials included raters with no or only limited
transplant experience. It is possible that both the inclu-
sion of raters with transplant experience (but who did
not have experience with the NIH criteria) as well as
the improved teaching materials jointly accounted
for the improved reliability estimates observed in the
final 2 trials.
That we observed high agreement in scoring gas-
trointestinal symptoms was not unexpected because
these symptoms are not observed by clinicians and
must be elicited directly from patients [16]. In addi-
tion, the prevalence of gastrointestinal complaints in
our sample was generally low. Consistent with the
findings of prior research demonstrating that patientself-report is the most valid method to evaluate symp-
tom severity and that healthcare providers misestimate
symptom intensities [17,18], clinician-expert pairs
were only moderately concordant in evaluating
cGVHD global symptom severity on a 10-point scale.
The modest level of concordance observed between
experts and clinicians in rating cGVHD as better,
worse, or stable on a 7-point scale may represent an ar-
tifact of our study design because the experts and the
clinicians each evaluated study participants at only 1
time point. Thus, it must be assumed that the raters
derived their scores through discussion with the
patient or based on speculation. It is plausible that
this feature of our study design introduced measure-
ment error that would not be observed with serial
evaluations. Future research conducted with raters
who have direct knowledge of subjects’ clinical status
over time is warranted to estimate the reliability of
the 7-point global evaluations of chronic GVHD as
better, worse, or stable.
Clinician participants offered a generally favorable
evaluation of the training session, opportunities for
skills practice, documentation tools, and the photo
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assessments into practice were acknowledged by par-
ticipants. However, it should be noted that the NIH
response assessments have been developed as outcome
measures in clinical trials and were not intended for
routine use in clinical care. Although it required
a median of 21 minutes for the clinician to conduct
and document the entire response evaluation, the
Schirmer tear test was the most time-consuming single
component of the evaluation, requiring a median of
9 minutes. Therefore, the response evaluation time
could be shortened to approximately 10 minutes at
many centers where the evaluation of the Schirmer
tear test, grip strength, and 2-minute walk test can be
delegated to other staff, thus conserving clinician
effort during busy clinics.
In the final 2 trials, the only ICC below 0.40 was
observed for the evaluation of movable sclerotic fea-
tures (ICC 5 0.24), and examination of the Bland-
Altman plots suggested a tendency for the novice
clinician raters to score a greater extent of involvement
with movable sclerosis relative to the experts. There
are several possible reasons why the measurement of
movable sclerosis poses particular difficulty compared
with the measurement of erythema or nonmovable
sclerosis. In some cases, movable sclerotic cGVHD
manifestations may be subtle and difficult to distin-
guish from nonsclerotic changes. Gauging movable
sclerotic manifestations is also a complex determina-
tion because the evaluator is required to integrate
visual and tactile assessments to formulate the score.
In addition, the margins of movable sclerotic involve-
ment can be challenging to define, whereas in contrast,
in patients with nonmovable sclerosis/hidebound
manifestations, differentiating affected and unaffected
areas is perhaps less subtle. Furthermore, in some
cases, movable cutaneous changes, particularly in the
setting of other manifestations, such as edema, may
mask underlying nonmovable sclerosis, making it diffi-
cult to distinguish the percent BSA associated with
each type of involvement. Our observation that novice
clinician raters in the final trial tended to overestimate
movable sclerosis and underestimate nonmovable scle-
rosis is consistent with this possibility. If this finding is
replicated in larger samples, clearer definitions to help
distinguish between movable and nonmovable sclero-
sis should be considered to achieve greater reliability
between raters. Future research to develop digitized,
computer analyzed methods for estimating percent of
BSA involved with specific cutaneous manifestations
[19,20] may also contribute to improvements in
making such distinctions.
Other approaches to reducing measurement error
include opportunities for practice, careful calibration
among raters, improvements in the design of assess-
ment tools, and using an average of multiple indepen-
dent ratings rather than a single rating [21,22]. A moreprecise operational definition of what constitutes
movable sclerosis and improvements to the photo
atlas and training materials may also improve the
interrater reliability between clinicians and experts.
For example, revision of the definitions of movable
sclerosis to incorporate textural changes might
increase clinicians’ precision in recognizing and
measuring this subtle manifestation.
Determining whether change has occurred in
response to therapy requires reliable measures of ther-
apeutic response. Two prior studies have specifically
addressed the interrater reliability of a component of
therapeutic response in cGVHD [23,24]. Our ICC
coefficients for the cutaneous manifestations of
erythema and nonmovable sclerosis are comparable
to those estimates reported by Greinix et al. [23] in
their evaluation of a scoring system focused on the cu-
taneous manifestations of cGVHD. However, the
Greinix et al. study examined the concordance among
4 raters, only 1 of whom was described as an expert,
whereas we report pairwise agreement between experts
and 34 clinicians across a wide range of patients. Treis-
ter et al. [24] assessed the interrater reliability among
transplant clinicians who evaluated oral cGVHDman-
ifestations through the use of photos. Although the in-
trarater reliability of assessments performed 1 week
apart was excellent, interrater reliability of assessments
based on the photos was poor to moderate (0.15-0.46).
One-half of the participants in the Treister et al. [24]
study noted that training would have improved their
accuracy in evaluating oral cGVHD manifestations,
and the incremental improvement in reliability ob-
served in our study suggests that even brief training
strengthens clinicians’ oral cGVHD assessment skills.
The range of ICC coefficients observed in our study
also parallels values that have been reported for the
psychometric evaluation of clinical examination
methods [25] and scoring systems for grading derma-
tologic, oral, and rheumatologic disease manifesta-
tions [26-31].
With replication in a larger sample, our preliminary
estimates of the interrater reliability, and thus the
minimum metrically detectable change that exceeds
measurement error, may be helpful in future studies
for power analysis and sample size estimation and to
interpret the results of prospective clinical trials
[32,33]. For example, if a new antifibrotic agent reduces
the extent of cutaneous sclerosis from a mean of 60%
BSA involvement to a mean of 30% BSA involvement
in the sample, knowing that the MDC95 is 17% BSA,
permits a conclusion that there has been a true
therapeutic effect. The minimum metrically detectable
change is distinct from, but complementary to,
definitions of clinically significant response (partial and
complete responses) [12,13]. Estimates of the MDC95
could be particularly useful in detecting therapeutic
activity in early phase clinical trials of new agents.
1628 Biol Blood Marrow Transplant 17:1619-1629, 2011S. A. Mitchell et al.Prospective studies would then be needed to determine
the magnitude of change that constitutes a clinically
meaningful response.
Within-rater variation may partially account for
some of the variability we observed between raters.
Future studies should address this limitation by incor-
porating a more comprehensive design that considers
both within-observer and between-observer variation,
including the variation within and between expert
raters. Until further reliability studies have been con-
ducted in larger samples of children with cGVHD,
caution should be exercised when applying these inter-
rater reliability estimates in pediatric clinical trials.We
recognize that the sample size for this series of pilot
trials was also relatively small, and clinician raters
received just a single 2.5-hour training session with
no opportunity to gain experience in applying the
response criteria before conducting these one-time re-
sponse assessments on patients. Raters may have been
able to improve in their skill and accuracy with more
opportunity to practice these new skills on several
patients before obtaining the ratings used to calculate
these reliability estimates. However, a strength of
this study is that the interrater reliability estimates
were obtained in a naturalistic setting and involved
study participants exhibiting a wide range of cGVHD
manifestations. Moreover, to our knowledge, this is
the first study to test the feasibility and reproducibility
of a multidimensional set of cGVHD therapeutic re-
sponse criteria, and to evaluate the response criteria
in both adults and children.
Although these findings support a conclusion that
application of the NIH criteria in determining thera-
peutic response will contribute to uniformity of data
collection and advance standards in cGVHD clinical
trials, our findings point to several important direc-
tions for future research. There is a need to evaluate in-
ter- and intrarater reliability of the NIH cGVHD
response criteria in prospective studies, and to examine
the concurrent and predictive validity of the response
criteria. Evaluation of interrater reliability in a larger
sample of raters would permit the application of
multivariate techniques, such as receiver-operating
characteristic (ROC) analysis, and would help to over-
come the constraints inherent when generalizing esti-
mates of interrater agreement developed on small
samples of observers [34]. Composite elements in the
response criteria should be individually evaluated for
their reliability, validity, and sensitivity to change.
For example, studies examining the psychometric
properties, such as the test-retest reliability and sensi-
tivity to change of the 2-minute walk distance and grip
strength in the cGVHD population, will contribute to
greater precision in our estimates of reproducibility
and will assist in defining clinically meaningful change.
Similarly, research is warranted to compare the
performance of methods to quantify cGVHD oculardisease manifestations (eg, Schirmer tear test, tear
film breakup time, tear osmolarity) [35], and to iden-
tify the method(s) with greatest reliability, specificity,
and sensitivity to change. Research to determine the
effect that raters’ level of transplant and cGVHD
experience has on the achievement of sufficiently
reliable scoring is needed. Future studies are also
indicated to determine if more intensive training
that includes repetition, calibration, and feedback on
performance from experts in cGVHD cutaneous
manifestations, and the use of standardized patients
and simulation, will improve the accuracy with which
cutaneous manifestations are recognized and scored.
Lastly, the evaluation of cGVHD therapeutic re-
sponse is an area that would benefit from efforts to
develop intermediate endpoints of response including
biomarkers, and to automate and digitize assessments
through refined instrumentation, imaging methods,
and computer-based applications [20,36-39], thus
improving reliability by limiting potential sources of
measurement error.ACKNOWLEDGMENTS
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